- VC firm Vivo Capital outlays $740m for biotech investment Pharmaceutical Technology
- Vivo Capital secures $740M to invest in preclinical- and clinical-stage biotechs Fierce Biotech
- Vivo Capital Closes Opportunity Fund FIN News
- Vivo Capital closes on $740m for third cycle of evergreen public fund Venture Capital Journal
- Healthcare specialist Vivo Capital closes third Opportunity Fund cycle at $740m Alternatives Watch
The wire
More investor news
How AyaHQ turned a failed startup into a founder-building business – TechCabal
Octopus Ventures closes £20M pre-seed fund, doubling its predecessor – Dealroom
Norwest raises record $4bn Fund XVIII, up 33% on predecessor, to target US, India and Israel – AltAssets Private Equity News
Vietnam Int’l Finance Center, Touchstone Partners launch $100M 1:1 co-investment program for startups – TNGlobal – TNGlobal
The 81 Collection doubles fund size to $82m to target underserved US industries – AltAssets Private Equity News
CEE Startup & Tech Weekly: UFORCE’s €630M Round, AI Deals & New Funds – The Recursive